Cmed’s CEO talks to Innovations in Pharmaceutical Technology.
14 Dec 2017
Cmed’s CEO David Connelly shares his thoughts on how new technology can revolutionise and streamline data and trial processes in this month’s issue of Innovations in Pharmaceutical Technology.
Amongst others things, he walks us through the different methodologies used to capture data and how technology is now shaping the way CROs work. Want to learn more? You can read the full article here
This article is taken from Innovations in Pharmaceutical Technology January 2018, pages 14-15.
The past year in the field of cellular immunotherapy in hematological malignancies has been extremely exciting. We saw FDA approval of the first CAR-T therapy for patients with ALL and then additional approvals for certain types of lymphoma. With several cellular immunotherapy products in development, it is indeed a thrilling time to be involved in the clinical trials of these novel therapies. At the annual American Society of Hematology conference this year, I am looking forward to learning more of recent advances, successes and challenges in developing these therapeutics as we all work together to overcome these hematological diseases that affect so many.
Cmed to Demonstrate encapsia at Two Leading Oncology Meetings
13 Nov 2017
Cloud-based Clinical Data Suite to be Showcased at Clinical Operations in Oncology Trials Europe and the ASH Annual Meeting Cmed, an oncology focused, innovative technology-led CRO, today announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual Meeting, taking place 9-12 December in Atlanta, GA.
As a full-service CRO, Cmed has a strong reputation in delivering complex and demanding clinical trials across numerous oncology types, including various haematological indications, immuno-oncology, breast, lung, prostate and colorectal.